Skip to main content

Table 1 Patients’ baseline data and clinical characteristics

From: Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment

Variable Study sample
n = 56
N %
Gender
 females 50 89.3
 males 6 10.7
Age ± SD (range 43.3 ± 9.5 (21–60)
Previous lines of prophylactic medications
 Median value 3 (1–7)
Psychological comorbidities
 Anxiety 12 21.4
 Depression 12 21.4
 Anxiety and depression 10 17.9
 Bipolar disorder 3 5.4
 None 19 33.9